Court Vacated FDA Classification for AXIOFILL Product

The ruling forces the FDA to reconsider whether the product is a medical device or a biological product.

Updated on Sept. 23, 2026 in Healthcare

Isometric editorial illustration of a sterile laboratory vial on a steel base, representing regulatory reclassification. — A federal court in Georgia vacated the FDA's regulatory classification of the tissue product AXIOFILL, mandating a re-evaluation of its status. AI Illustration. Upload story photo >

Live Poll

Should regulatory agencies be required to explain why they classify similar medical products differently?

A federal court in Georgia vacated the FDA's regulatory classification of the tissue product AXIOFILL, ruling the agency's initial determination was arbitrary and capricious. This decision requires the FDA to re-evaluate the product's status as a biological product versus a medical device.

Why it matters

The ruling challenges how the FDA applies its minimal-manipulation regulation, potentially impacting the regulatory pathways for manufacturers of similar tissue-based products. Operators in the biotech space must monitor this reversal as it sets a precedent for how the FDA must justify classification discrepancies between comparable market offerings.

The U.S. District Court for the Northern District of Georgia vacated an FDA classification for AXIOFILL, a product that originally launched in 2022. The agency's next steps involve a court-mandated review of its minimal-manipulation criteria.

The players

U.S. District Court for the Northern District of Georgia

The federal judicial body with jurisdiction over cases in northern Georgia that oversees legal disputes involving federal regulatory actions.

FDA

The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and biological products.

The details

The Court held that the FDA incorrectly interpreted its minimal-manipulation regulation by focusing on the function of the placental disc in the donor rather than its utility for the recipient. The ruling further noted that the agency failed to adequately explain why AXIOFILL was classified differently than other similar products currently available on the market. The FDA is now required to reconsider the product's classification consistent with the court's order.

AXIOFILL was launched in 2022.
The District Court issued the ruling on September 23, 2026.

Market Landscape

This ruling challenges the FDA's established application of its minimal-manipulation regulation for Section 361 HCT/P products. It follows a pattern of heightened judicial scrutiny regarding how the agency justifies classification differences between similar medical products on the market.

Manufacturers and operators in the tissue-product sector should monitor the upcoming FDA reconsideration process for new guidance on minimal-manipulation definitions. Compliance teams should prepare for potential shifts in documentation requirements if the agency updates its classification standards.

The takeaway

The court's decision highlights the importance of holding regulators to consistent standards when classifying similar market products. Operators should track how the FDA updates its classification criteria in response to this order, as it may signal a shift in the regulatory environment for tissue-based medical devices.